|
|
Article: Glaxo Wellcome and SmithKline Beecham Merger Update: US Regulatory Clearance Obtained.
- Article from:
- PR Newswire
- Article date:
- December 18, 2000
CopyrightCOPYRIGHT 2000 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
PHILADELPHIA, Dec. 18 /PRNewswire/ --
Glaxo Wellcome (NYSE: GLX) and SmithKline Beecham (NYSE: SBH) today announce that the United States Federal Trade Commission (FTC) has approved the terms of a consent decree granting regulatory clearance for their merger to form GlaxoSmithKline. Glaxo Wellcome and SmithKline Beecham have now obtained all regulatory clearances required to complete the merger, as expected, on 27th December. As previously announced, in order to secure FTC approval for the merger, SmithKline Beecham has agreed to divest the anti-emetic product Kytril and the anti-viral products Famvir and Vectavir/Denavir. No further material divestitures have ...